Study Shows Tislelizumab Boosts Survival in Patients with Previously Treated Esophageal Cancer

A study published in July 2021 in the Journal of Clinical Oncology has shown that the overall survival (OS) in patients who had previously treated esophageal cancer improved significantly with the humanized monoclonal antibody drug tislelizumab when compared to chemotherapy (J Clin Oncol. 2021 39:15_suppl, 4012-4012; the study was sponsored by BeiGene, Ltd.).  In the global […]
Source: ENT Today - Category: ENT & OMF Authors: Tags: Online Exclusives clinical trials head and neck cancer Source Type: research